The transaction is contingent on competition clearances and other customary consents. Shire was advised by Rothschild.
Notes to Editors
1 Other products divested included: LODINE(R) (etodolac) for treatment of rheumatoid arthritis and osteoarthritis, COLAZIDE(R) (balsalazide) for treatment of mild to active ulcerative colitis, MEPTID(R) (meptazinol hydrochloride) for treatment of pain, CEBUTID(R) (flurbiprofen) for treatment of the symptoms of rheumatoid arthritis and osteoarthritis, ROBAXIN(R) (methocarbamol) for relief of pain from muscle injuries, spasms, sprains and strains, MINTEC(R) (peppermint oil) for the relief of discomfort associated with irritable bowel syndrome.
SOLARAZE is a topical preparation for the treatment of actinic keratoses, which are common skin lesions on areas damaged extensively by sunlight. VANIQA is a topical prescription medicine for treating unwanted facial hair in women.
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shir
|SOURCE Shire plc|
Copyright©2007 PR Newswire.
All rights reserved